Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pamrevlumab - FibroGen

Next Previous
Drug Profile

Pamrevlumab - FibroGen

Alternative Names: Anti-CTGF antibody - FibroGen; FG-3019

Latest Information Update: 29 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FibroGen
  • Class Antifibrotics; Antineoplastics; Antivirals; Cardiovascular therapies; Immunotherapies; Monoclonal antibodies; Urologics
  • Mechanism of Action Connective tissue growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy; Pancreatic cancer; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Duchenne muscular dystrophy; Idiopathic pulmonary fibrosis; Pancreatic cancer
  • Phase II/III COVID 2019 infections
  • Discontinued Diabetic cardiomyopathy; Diabetic nephropathies; Diabetic neuropathies; Glioblastoma; Glomerulonephritis; Hepatic fibrosis

Most Recent Events

  • 08 Dec 2023 FibroGen terminates phase III ZEPHYRUS-2 trial in Idiopathic Pulmonary Fibrosis (IPF) in US, Hong Kong, Taiwan, Argentina, Australia, Chile, China, Japan, South Korea and Russia, due to study does not meet its primary endpoint (NCT03955146)
  • 29 Sep 2023 Fibrinogen terminates the phase III LELANTOS-1 trial in Duchenne muscular dystrophy (In adolescents, In adults, In the elderly, Combination therapy, In Children) in USA, Australia, Austria, Belgium, Canada, China, Czech Republic, France, Israel, Italy, Netherlands, Spain, Switzerland and the UK (IV) (NCT04371666)
  • 27 Sep 2023 FibroGen terminated the phase II trial in Duchenne muscular dystrophy (In adolescents, In adults) in USA (IV) due to sponsor's decision (NCT02606136)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top